ROP.SW RO

ROP.SW ROCHE PS

Healthcare · Drug Manufacturers - General

4 · Weak Momentum 10.0 · Strong Safe Aristocrat

367.40

+1.80%

About the company

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and others; diagnostic instruments; and digital health solutions. Roche Holding AG has a collaboration agreement with Excalipoint Therapeutics to evaluate EXP011 in DLL3-expressing solid tumors. The company was founded in 1896 and is based in Basel, Switzerland.

2.67%
63.89%
9.80
292.7B
23.95
15.34
331.50

52-week range

367
low 252 high 375
Yield Growth Momentum Safety Value Health

Dividend deep dive

ROCHE PS (ROP.SW), operating in the Drug Manufacturers - General industry within the Healthcare sector, currently offers a dividend yield of 2.93%. This yield falls within its 5-year historical range of 2.68% (low) to 3.75% (high), and Yield Theory assesses its current status as "fair." The company's dividend safety is rated as "safe." Its market capitalization is not provided in the available data.

Dividend history

ROCHE PS has maintained a consistent record of dividend increases for 28 consecutive years, earning it a "champion" tier classification. The company distributes dividends annually, typically in March. Its dividend growth has been modest, with a 3-year Compound Annual Growth Rate (CAGR) of 1.41% and a 5-year CAGR of 1.51%. The annual dividend per share has progressed from CHF 7.8 in 2014 to CHF 9.5 in 2023, with CHF 9.6 projected for 2024 and CHF 9.7 for 2025.

Dividend safety

The dividend coverage for ROCHE PS appears robust, with a payout ratio of 61.06% against its earnings, contributing to its "safe" dividend safety status. The balance sheet indicates a debt-to-equity ratio of 87.637%.

Quantic · Free

Read the rest of the safety verdict

Plus the key risks and what to watch next — free, no card.

AI-generated from Quantic's dividend data · Updated 17 Jul 2026 · Information, not financial advice.

Price history

379 300 221 2021 2022 2023 2024 2025 2026 2020-07 · 316 2020-08 · 315 2020-09 · 295 2020-10 · 299 2020-11 · 309 2020-12 · 307 2021-01 · 298 2021-02 · 305 2021-03 · 298 2021-04 · 313 2021-05 · 349 2021-06 · 350 2021-07 · 368 2021-08 · 342 2021-09 · 354 2021-10 · 360 2021-11 · 379 2021-12 · 357 2022-01 · 350 2022-02 · 366 2022-03 · 362 2022-04 · 326 2022-05 · 319 2022-06 · 315 2022-07 · 315 2022-08 · 323 2022-09 · 333 2022-10 · 308 2022-11 · 291 2022-12 · 285 2023-01 · 272 2023-02 · 261 2023-03 · 280 2023-04 · 288 2023-05 · 274 2023-06 · 271 2023-07 · 260 2023-08 · 250 2023-09 · 234 2023-10 · 236 2023-11 · 245 2023-12 · 247 2024-01 · 232 2024-02 · 230 2024-03 · 221 2024-04 · 231 2024-05 · 250 2024-06 · 286 2024-07 · 287 2024-08 · 271 2024-09 · 268 2024-10 · 256 2024-11 · 256 2024-12 · 286 2025-01 · 299 2025-02 · 291 2025-03 · 269 2025-04 · 266 2025-05 · 258 2025-06 · 257 2025-07 · 260 2025-08 · 260 2025-09 · 259 2025-10 · 307 2025-11 · 328 2025-12 · 351 2026-01 · 367 2026-02 · 315 2026-03 · 318 2026-04 · 329 2026-05 · 333 2026-06 · 330 2026-07 · 332
Price

Dividend profile

Frequency
Annual
Growth (TTM)
+1.0%
CAGR 3y
+1.4%
+1.5%
28 years

(5-year)

Now 2.7%
2.7% avg 3.3% 3.8%

Payment calendar

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec

Dividend history

CAGR 3y +1.4% CAGR 5y +1.5% 28y streak
14 15 16 17 18 19 20 21 22 23 24 25

Per-share dividend by year

Quantic · Free

Unlock valuation & strategy

Two DDM fair values, margin of safety, sector value rank, Dividend Yield Theory, doubling time and max drawdown.

Debt & leverage

87.6%
1.38
1.05
Debt vs cash
Debt Cash
Total debt
33.2B CHF
Total cash
15.5B CHF
24.0B CHF

Latest reported balance-sheet figures.

Held by 1 investor · watched by 1

Appears in these lists

ROP.SW qualifies for these curated dividend rankings.

Information, not financial advice.

Quantic · Free

Track ROP.SW and your whole portfolio

Real yield, dividend safety, net-of-tax income and your path to freedom — free, no broker connection.

€0

Need more? Pro adds portfolios, options income tracking & more AI. See Pro →